Immunotherapies, especially immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR) T cell therapy, depend on functional T cells. Yet T cells in the tumor microenvironment (TME) face a gauntlet of genotoxic pressures: rapid proliferation and T cell receptor (TCR) activation generate replication stress and reactive oxygen species (ROS); regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) starve or chemically modify lymphocytes; and chemotherapy, radiotherapy, and DNA damage response inhibitors (DDRi) add further breaks. Most research has treated T cells as passive bystanders to tumor-intrinsic DNA damage, leaving the consequences of damage within T cells largely unexplored. Because these lesions may limit the durability of otherwise effective regimens, the origins, repair capacity, and functional outcomes of T cell DNA damage need deeper investigation.
Researchers from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Wuhan University in China published (DOI: /10.20892/j.issn.2095-3941.2026.0020)the review in Cancer Biology & Medicine. The article synthesizes evidence on how DNA damage arises in T cells and how it can be measured and mitigated. The authors report no conflicts of interest. The work was supported by the National Key Technology Research and Development Program of China and the National Natural Science Foundation of China, among other funders.
The review's central insight is that DNA damage in T cells is not a single phenomenon but a spectrum. Oxidative base lesions and single-strand breaks dominate in the ROS-rich TME and depend on poly(ADP-ribose) polymerase (PARP)-mediated repair; replication stress engages the ataxia telangiectasia and Rad3-related (ATR)-checkpoint kinase 1 (CHK1) axis; and double-strand breaks are handled by ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Resting T cells assemble repair foci poorly, whereas activated T cells repair more efficiently but also accumulate more damage. Susceptibility varies by subset: exhausted T cells (TEX) show the largest rise in phosphorylated ATM (pATM), and terminally differentiated effector memory T cells (TEMRA) are more vulnerable than stem cell-like memory T cells (TSCM), which repair DNA well and express less caspase-3. Mechanistically, chronic activation upregulates CD38, an NAD+ hydrolase that depletes the NAD+ pool needed for PARP activity, while tumors and Tregs amplify damage through glucose competition and nitric oxide (NO) release. Downstream, p53- and JNK/p73-dependent apoptosis, reduced granzyme B (GZMB) and interferon-gamma (IFN-γ) production, impaired TCF1-driven memory formation, upregulation of PD-1 and TIM-3, and telomere erosion all follow. The authors also flag a paradox: PARP inhibitors (PARPi) can trap PARP1 in T cells and worsen damage, even as they make tumors more immunogenic.
The authors said the field has spent years optimizing how much DNA damage can be inflicted on a tumor, often without asking what the same treatment does to the immune cells meant to finish the job. They said T cells are not uniform, so blanket assumptions about toxicity miss the subsets that matter most for durable responses. According to the authors, the goal is not weaker tumor killing but smarter scheduling and rational combinations that leave T cells time and capacity to repair. They said they hope the framework pushes trial designers to measure repair capacity and damage-associated phenotypes in T cell subsets, rather than treating immune toxicity as an afterthought.
The review maps several ways to protect T cells without sacrificing antitumor activity. Boosting NAD+ with β-nicotinamide mononucleotide (NMN) or blocking CD38 restored PARP-dependent repair and improved T cell expansion and cytotoxicity in mice. Inhibiting inducible nitric oxide synthase (iNOS) or supplementing glucose eased TME-driven damage, and ATM or p38 inhibitors reduced damage when combined with adoptive transfer or ICBs in preclinical models. Sequential dosing of DDRi, lower or intermittent schedules, non-trapping PARPi, and editing PARP1 in T cells could widen the therapeutic window. In manufacturing, editing before activation and using the CasPLUS editing tool limited chromosomal loss. The authors also propose pATM and 8-hydroxy-2'-deoxyguanosine (8-OHdG) as candidate biomarkers for patient stratification and response monitoring.
###
References
DOI
10.20892/j.issn.2095-3941.2026.0020
Original Source URL
https://doi.org/10.20892/j.issn.2095-3941.2026.0020
Funding information
This study was supported by the National Key Technology Research and Development Program of China (Grant No. 2022YFC2704200 to Qinglei Gao), the National Natural Science Foundation of China (Grant Nos. U25A20117 and 82372928 to Qinglei Gao), Noncommunicable Chronic Diseases-National Science and Technology Major Project (Grant No. 2024ZD0534100 to Jiahao Liu), Beijing Xisike Clinical Oncology Research Foundation (to Xiaofei Jiao and Qinglei Gao), and Project of Hubei health commission (Grant No. WJ2025Q033 to Jiahao Liu).
About Cancer Biology & Medicine
Cancer Biology & Medicine (CBM) is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 12.4), with all full texts freely visible to clinicians and researchers all over the world (http://www.ncbi.nlm.nih.gov/pmc/journals/2000/).